Initially introduced in 2005, GLP-1 RAs found their primary application in the treatment of type 2 diabetes (T2DM), demonstrating exceptional efficacy and a commendable safety profile in this domain [8–10]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.